U.S. markets open in 3 hours 10 minutes

Tenax Therapeutics, Inc. (TENX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.1842+0.0124 (+7.22%)
At close: 04:00PM EDT
0.1821 -0.00 (-1.14%)
After hours: 07:40PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Short-term KST

Short-term KST

Previous Close0.1718
Bid0.1333 x 800
Ask0.1930 x 3200
Day's Range0.1700 - 0.1900
52 Week Range0.1600 - 1.9590
Avg. Volume430,979
Market Cap4.643M
Beta (5Y Monthly)2.09
PE Ratio (TTM)N/A
EPS (TTM)-0.4920
Earnings DateNov 14, 2022 - Nov 18, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for TENX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Tenax Therapeutics, Inc.
    The Argus Mid-Cap Model PortfolioSmall- and mid-cap stocks (SMID stocks) have underperformed large-caps over the past 12 months, but still may be in a better position to generate market-beating returns going forward. For one thing, SMID companies tend to focus on domestic markets, so their businesses could be less disrupted by the fallout from the Russian invasion of Ukraine. As well, the prices of SMID stocks generally are lower than the prices of large-caps. SMID stocks can be risky -- and large-caps outperformed SMID stocks in 11 of the 19 years in our test period. Still, despite the risks, diversified investors look to have exposure to small- and mid-caps based on the long-term performance record. We estimate that 12%-15% of the U.S. stock market's capitalization is comprised of SMID stocks. For our purposes, we use a threshold of $20 billion to define a SMID stock.
    Fair Value
    Economic Moat
    4 days agoArgus Research
View more
  • Benzinga

    Tenax Therapeutics Stock Jumps On Strategic Alternative Review

    Tenax Therapeutics Inc (NASDAQ: TENX) is evaluating alternative strategic paths. Roth Capital Partners will support Tenax Therapeutics as its financial advisor in this process. Tenax Therapeutics and its Board of Directors believe the company's current valuation does not accurately reflect the potential value of its clinical-stage pipeline. Tenax Therapeutics is developing two Phase 3 ready assets - TNX-201 (modified release imatinib) for pulmonary arterial hypertension (PAH) and TNX-103 (oral l

  • GlobeNewswire

    Tenax Therapeutics Announces the Evaluation of Strategic Alternatives

    MORRISVILLE, N.C., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that the Company is evaluating alternative strategic paths focused on maximizing shareholder value. Roth Capital Partners will support Tenax Therapeutics as its financial advisor in this process. Tenax Therape

  • Simply Wall St.

    Loss-Making Tenax Therapeutics, Inc. (NASDAQ:TENX) Expected To Breakeven In The Medium-Term

    We feel now is a pretty good time to analyse Tenax Therapeutics, Inc.'s ( NASDAQ:TENX ) business as it appears the...